Revelyx Bio Phase 2 data back recombinant liquid botulinum toxin YY003
Revelyx Bio has reported positive topline results from its Phase 2 study of YY003, an investigational recombinant botulinum toxin type A supplied as a ready-to-use liquid, in adults with moderate-to-severe glabellar lines. The Nashville-based company said the trial met its primary and all key secondary endpoints, and it intends to request an End-of-Phase-2 meeting with the US Food and Drug Administration to discuss a pivotal programme.
The two-part study (NCT06481475) randomised 153 adults across three sites in Australia under a US Investigational New Drug application. Part B enrolled 129 participants in a double-blind, vehicle-controlled comparison of 30-unit and 40-unit doses, with the 40-unit arm delivering the headline figures.
Clinical results
The composite primary endpoint at week four required both the investigator and the participant independently to record a score of none or mild on the Facial Wrinkle Scale and at least a two-grade improvement from baseline. At 40 U, 80.8% of participants met that criterion versus 0% in the vehicle group (p less than 0.001); the 30-unit arm returned a composite response rate of 66.7%.
The early-onset profile attracted attention: 90.4% of the 40-unit group achieved a none-or-mild rating by week one, approaching the week-four result of 92.3%, compared with 3.8% for vehicle. Patient-reported outcomes were broadly consistent, with 94.2% of the 40-unit group reporting improvement on the Global Aesthetic Improvement Scale and 90.4% reporting satisfaction with the appearance of their frown lines.
On immunogenicity, no neutralising antibodies were detected in any participant, and only one of 106 participants tested positive for anti-drug antibodies while maintaining clinical response. The most common treatment-related adverse events were injection-site reactions and headache; no treatment-related serious adverse events occurred and no participant discontinued due to an adverse event.
Principal investigator Professor Gregory Goodman, director of the Dermatology Institute of Victoria, described the dual-assessment primary endpoint as "rigorous" and noted that the liquid formulation could "eliminate manual reconstitution and simplify product preparation" relative to current marketed products.
Market context and competitive positioning
YY003 is produced through recombinant expression in E. coli rather than by purification from Clostridium botulinum cultures, a process that Claruvis Pharmaceutical, the Chinese licensor and development partner, says offers tighter control over neurotoxin identity and purity. The product is supplied ready to use, removing the reconstitution step that is currently required for all botulinum toxin type A products approved in the United States.
The global aesthetic botulinum toxin market is mature and concentrated, dominated by Allergan Aesthetics (onabotulinumtoxinA, Botox), Galderma (prabotulinumtoxinA-xvfs, Dysport) and Evolus (prabotulinumtoxinA, Jeuveau). A ready-to-use liquid format is a meaningful practical differentiator for clinic workflow, though its commercial weight will depend on the price point Revelyx sets and whether payers and practitioners regard preparation time as a material cost. Recombinant manufacture, if it supports a cleaner immunogenicity profile over repeat dosing, may become a more significant clinical differentiator as long-term datasets accumulate.
Claruvis's parent company, MingMed Biotechnology, already markets Retoxin (YY001), described as the world's first approved recombinant botulinum toxin type A, in China. Revelyx holds commercialisation rights for all territories outside mainland China, Hong Kong, and Macau, giving it a broad but currently unpartnered commercial footprint to build.
The next catalysts for Revelyx will be the FDA's response to the End-of-Phase-2 meeting request and the design of a pivotal study, including dose selection and whether the agency requires additional comparator-controlled arms or a specific safety follow-up period given the repeat-dosing nature of the aesthetic indication.